Availability of antiepileptic drugs across Europe

Arton Baftiu, Cecilie Johannessen Landmark, Valent Nikaj, Inger Lise Neslein, Svein I. Johannessen, Emilio Perucca

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Summary Europe consists of 53 countries with widely different economic conditions and different political, educational, and health care systems. This study was aimed at determining the availability of antiepileptic drugs (AEDs) across Europe. An electronic questionnaire was submitted to all 43 European chapters of the International League Against Epilepsy (ILAE). Outcome measures were availability of older, newer, and newest AEDs, generic products, indications, reimbursement rules, and reasons for lack of availability of AEDs. Countries were divided according to economic status as defined by the World Bank. Thirty-four chapters (79%) provided data. There were large differences in AED availability across countries, especially between high-income countries and the other countries. The newest AEDs were not available in any of the 12 non-high-income countries. Availability was higher in countries with public reimbursement systems. Reimbursement policies ranged from full reimbursement for all AEDs to complete lack of reimbursement. Main hurdles for poor access to AEDs included lack of regulatory approval, high prices and reimbursement restrictions. The availability of AEDs differs across European countries, with many hurdles hampering access to epilepsy medicines, particularly to new medications. These findings raise major concerns on the quality of epilepsy care in many countries.

Original languageEnglish
Pages (from-to)e191-e197
JournalEpilepsia
Volume56
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Anticonvulsants
Epilepsy
Economics
United Nations
Quality of Health Care
Outcome Assessment (Health Care)
Delivery of Health Care

Keywords

  • Antiepileptic drugs
  • Availability
  • Drug utilization
  • Epilepsy
  • Europe
  • Treatment gap

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Baftiu, A., Johannessen Landmark, C., Nikaj, V., Neslein, I. L., Johannessen, S. I., & Perucca, E. (2015). Availability of antiepileptic drugs across Europe. Epilepsia, 56(12), e191-e197. https://doi.org/10.1111/epi.13210

Availability of antiepileptic drugs across Europe. / Baftiu, Arton; Johannessen Landmark, Cecilie; Nikaj, Valent; Neslein, Inger Lise; Johannessen, Svein I.; Perucca, Emilio.

In: Epilepsia, Vol. 56, No. 12, 01.12.2015, p. e191-e197.

Research output: Contribution to journalArticle

Baftiu, A, Johannessen Landmark, C, Nikaj, V, Neslein, IL, Johannessen, SI & Perucca, E 2015, 'Availability of antiepileptic drugs across Europe', Epilepsia, vol. 56, no. 12, pp. e191-e197. https://doi.org/10.1111/epi.13210
Baftiu A, Johannessen Landmark C, Nikaj V, Neslein IL, Johannessen SI, Perucca E. Availability of antiepileptic drugs across Europe. Epilepsia. 2015 Dec 1;56(12):e191-e197. https://doi.org/10.1111/epi.13210
Baftiu, Arton ; Johannessen Landmark, Cecilie ; Nikaj, Valent ; Neslein, Inger Lise ; Johannessen, Svein I. ; Perucca, Emilio. / Availability of antiepileptic drugs across Europe. In: Epilepsia. 2015 ; Vol. 56, No. 12. pp. e191-e197.
@article{adf6b0c0ef064ef890066edf7feff048,
title = "Availability of antiepileptic drugs across Europe",
abstract = "Summary Europe consists of 53 countries with widely different economic conditions and different political, educational, and health care systems. This study was aimed at determining the availability of antiepileptic drugs (AEDs) across Europe. An electronic questionnaire was submitted to all 43 European chapters of the International League Against Epilepsy (ILAE). Outcome measures were availability of older, newer, and newest AEDs, generic products, indications, reimbursement rules, and reasons for lack of availability of AEDs. Countries were divided according to economic status as defined by the World Bank. Thirty-four chapters (79{\%}) provided data. There were large differences in AED availability across countries, especially between high-income countries and the other countries. The newest AEDs were not available in any of the 12 non-high-income countries. Availability was higher in countries with public reimbursement systems. Reimbursement policies ranged from full reimbursement for all AEDs to complete lack of reimbursement. Main hurdles for poor access to AEDs included lack of regulatory approval, high prices and reimbursement restrictions. The availability of AEDs differs across European countries, with many hurdles hampering access to epilepsy medicines, particularly to new medications. These findings raise major concerns on the quality of epilepsy care in many countries.",
keywords = "Antiepileptic drugs, Availability, Drug utilization, Epilepsy, Europe, Treatment gap",
author = "Arton Baftiu and {Johannessen Landmark}, Cecilie and Valent Nikaj and Neslein, {Inger Lise} and Johannessen, {Svein I.} and Emilio Perucca",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/epi.13210",
language = "English",
volume = "56",
pages = "e191--e197",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "12",

}

TY - JOUR

T1 - Availability of antiepileptic drugs across Europe

AU - Baftiu, Arton

AU - Johannessen Landmark, Cecilie

AU - Nikaj, Valent

AU - Neslein, Inger Lise

AU - Johannessen, Svein I.

AU - Perucca, Emilio

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Summary Europe consists of 53 countries with widely different economic conditions and different political, educational, and health care systems. This study was aimed at determining the availability of antiepileptic drugs (AEDs) across Europe. An electronic questionnaire was submitted to all 43 European chapters of the International League Against Epilepsy (ILAE). Outcome measures were availability of older, newer, and newest AEDs, generic products, indications, reimbursement rules, and reasons for lack of availability of AEDs. Countries were divided according to economic status as defined by the World Bank. Thirty-four chapters (79%) provided data. There were large differences in AED availability across countries, especially between high-income countries and the other countries. The newest AEDs were not available in any of the 12 non-high-income countries. Availability was higher in countries with public reimbursement systems. Reimbursement policies ranged from full reimbursement for all AEDs to complete lack of reimbursement. Main hurdles for poor access to AEDs included lack of regulatory approval, high prices and reimbursement restrictions. The availability of AEDs differs across European countries, with many hurdles hampering access to epilepsy medicines, particularly to new medications. These findings raise major concerns on the quality of epilepsy care in many countries.

AB - Summary Europe consists of 53 countries with widely different economic conditions and different political, educational, and health care systems. This study was aimed at determining the availability of antiepileptic drugs (AEDs) across Europe. An electronic questionnaire was submitted to all 43 European chapters of the International League Against Epilepsy (ILAE). Outcome measures were availability of older, newer, and newest AEDs, generic products, indications, reimbursement rules, and reasons for lack of availability of AEDs. Countries were divided according to economic status as defined by the World Bank. Thirty-four chapters (79%) provided data. There were large differences in AED availability across countries, especially between high-income countries and the other countries. The newest AEDs were not available in any of the 12 non-high-income countries. Availability was higher in countries with public reimbursement systems. Reimbursement policies ranged from full reimbursement for all AEDs to complete lack of reimbursement. Main hurdles for poor access to AEDs included lack of regulatory approval, high prices and reimbursement restrictions. The availability of AEDs differs across European countries, with many hurdles hampering access to epilepsy medicines, particularly to new medications. These findings raise major concerns on the quality of epilepsy care in many countries.

KW - Antiepileptic drugs

KW - Availability

KW - Drug utilization

KW - Epilepsy

KW - Europe

KW - Treatment gap

UR - http://www.scopus.com/inward/record.url?scp=84950275630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950275630&partnerID=8YFLogxK

U2 - 10.1111/epi.13210

DO - 10.1111/epi.13210

M3 - Article

C2 - 26477534

AN - SCOPUS:84950275630

VL - 56

SP - e191-e197

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 12

ER -